![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA APPROVES TARO'S GENERIC EXTENDED-RELEASE PHENYTOIN
FDA APPROVES TARO'S GENERIC EXTENDED-RELEASE PHENYTOIN
Taro Pharmaceutical Industries has received approval from the FDA for its abbreviated new drug application for extended-release phenytoin capsules 100 mg.
Phenytoin is prescribed for treating seizures related to epilepsy and neurosurgery. The Taro product is bioequivalent to Pfizer's Dilantin Kapseals. According to industry sources, extended-release phenytoin capsule products have annual U.S. sales of approximately $191 million.
In addition, Taro Pharmaceuticals Ireland received approvals from the FDA in August for sodium chloride injection 0.9 percent and water for injection, packaged in single-dose plastic ampules. These are the first two ANDA approvals received by Taro's Irish affiliate.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct